Alexey V. Mazurov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexey V. Mazurov has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Ольга Александровна Шустова
National Medical Research Center of Cardiology
4 shared publications - Svetlana G. Khaspekova
Chazov National Medical Research Center of Cardiology, Russian Ministry of Health, Academician Chazov Str., 15a, Moscow 121552, Russia
3 shared publications Beat Steiner
F. Hoffmann La-Roche Ltd., Pharma Research, Basel, Switzerland
1 shared publication- Dmitry V. Pevzner
Chazov National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation; M.F. Vladimirsky Moscow Regional Research and Clinical Institute
1 shared publication - Elena N. Lipets
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow, Russia
1 shared publication F I Ataullakhanov
Department of Biophysics, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
1 shared publication
Latest Publications
- 30 April 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (4) , 64-72
The role of platelet glycoprotein IIb / IIIa inhibitors in current treatment of acute coronary syndrome
Current management of patients with acute coronary syndrome (ACS) includes a dual antiplatelet therapy with acetylsalicylic acid and a platelet P2Y12 receptor inhibitor. For patients without a high risk of bleeding, prasugrel and ticagrelor are preferred, since their effect is more pronounced, less dependent on metabolism of a specific patient, and occurs faster that the effect of clopidogrel. The prescription rate of platelet glycoprotein IIb/IIIa (GP IIb / IIIa) receptor inhibitors has considerably decreased. However, these drugs remain relevant in percutaneous coronary interventions in patients with a high risk of coronary thrombosis or a massive coronary thrombus, in thrombotic complications of the procedure, and in the “no-reflow” phenomenon. The intravenous route of GP IIb / IIIa inhibitor administration provides their effectiveness in patients with difficulties of drug intake or with impaired absorption of oral medications. This review presents clinical and pharmacological characteristics of various GP IIb / IIIa inhibitors and data of randomized clinical studies and registries of recent years that evaluated results of their use in patients with ACS.
- 30 April 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (4) , 64-72
The role of platelet glycoprotein IIb / IIIa inhibitors in current treatment of acute coronary syndrome
Current management of patients with acute coronary syndrome (ACS) includes a dual antiplatelet therapy with acetylsalicylic acid and a platelet P2Y12 receptor inhibitor. For patients without a high risk of bleeding, prasugrel and ticagrelor are preferred, since their effect is more pronounced, less dependent on metabolism of a specific patient, and occurs faster that the effect of clopidogrel. The prescription rate of platelet glycoprotein IIb/IIIa (GP IIb / IIIa) receptor inhibitors has considerably decreased. However, these drugs remain relevant in percutaneous coronary interventions in patients with a high risk of coronary thrombosis or a massive coronary thrombus, in thrombotic complications of the procedure, and in the “no-reflow” phenomenon. The intravenous route of GP IIb / IIIa inhibitor administration provides their effectiveness in patients with difficulties of drug intake or with impaired absorption of oral medications. This review presents clinical and pharmacological characteristics of various GP IIb / IIIa inhibitors and data of randomized clinical studies and registries of recent years that evaluated results of their use in patients with ACS.
- Open Access
- 13 July 2021
- Published by Remedium, Ltd. in Atherothrombosis
- No. 1,p. 144-156
Reticulated platelets – a new risk factor of atherothrombosis?
In this review we described the properties of reticulated platelets (RP) and showed how variations of their content might influence platelet activity, efficacy of antiplatelet drugs and the rate of thrombotic events in patients with cardiovascular diseases. RP represent a minor platelet fraction containing residual RNA from megakaryocytes. Platelets have no nucleus and do not synthesize RNA de novo, and RNA of megakaryocytic origin is destroyed during their circulation. That is why only recently produced “young” platelets contain RNA. In healthy donors RP are identified by staining with the RNA specific fluorescent dyes by flow cytofluorimetry or using standard protocols in modern flow haematological analyzers. RP content in blood reflects the level of thrombocytopoesis in the bone marrow. RP on average amounted from 3 to 10% of all platelets in the circulation depending on the method applied for their determination. RP absolute amount and/or their percentage is changed in haematological diseases associated with the alterations of megakaryocyte productive properties. RT measurements in patients with cardiovascular diseases have shown that their content is increased in acute coronary syndrome patients. RP are larger and functionally more active in comparison with not reticulated forms. They more frequently incorporate into the platelet aggregates and contain more intracellular granules. Increase of RT content in the circulation correlates with the increase of the average size and functional activity in the whole platelet population. High RP content in patients with cardiovascular diseases reduces antiaggregative effects of aspirin and P2Y12 APD receptor antagonists and increases the risk of atherothrombotic events.
- 13 July 2021
- Published by Remedium, Ltd. in Atherothrombosis
- No. 1,p. 144-156
Open AccessReticulated platelets – a new risk factor of atherothrombosis?
In this review we described the properties of reticulated platelets (RP) and showed how variations of their content might influence platelet activity, efficacy of antiplatelet drugs and the rate of thrombotic events in patients with cardiovascular diseases. RP represent a minor platelet fraction containing residual RNA from megakaryocytes. Platelets have no nucleus and do not synthesize RNA de novo, and RNA of megakaryocytic origin is destroyed during their circulation. That is why only recently produced “young” platelets contain RNA. In healthy donors RP are identified by staining with the RNA specific fluorescent dyes by flow cytofluorimetry or using standard protocols in modern flow haematological analyzers. RP content in blood reflects the level of thrombocytopoesis in the bone marrow. RP on average amounted from 3 to 10% of all platelets in the circulation depending on the method applied for their determination. RP absolute amount and/or their percentage is changed in haematological diseases associated with the alterations of megakaryocyte productive properties. RT measurements in patients with cardiovascular diseases have shown that their content is increased in acute coronary syndrome patients. RP are larger and functionally more active in comparison with not reticulated forms. They more frequently incorporate into the platelet aggregates and contain more intracellular granules. Increase of RT content in the circulation correlates with the increase of the average size and functional activity in the whole platelet population. High RP content in patients with cardiovascular diseases reduces antiaggregative effects of aspirin and P2Y12 APD receptor antagonists and increases the risk of atherothrombotic events.
- Open Access
- 29 May 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (5) , e0227932
Use of Thrombodynamics for revealing the participation of platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation
For many pathological states, microparticles are supposed to be one of the causes of hypercoagulation. Although there are some indirect data about microparticles participation in coagulation activation and propagation, the integral hemostasis test Thrombodynamics allows to measure micropaticles participation in these two coagulation phases directly. Demonstrates microparticles participation in coagulation activation by influence on the appearance of coagulation centres in the plasma volume and the rate of clot growth from the surface with immobilized tissue factor.Methods: Microparticles were obtained from platelets and erythrocytes by stimulation with thrombin receptor-activating peptide (SFLLRN) and calcium ionophore (A23187), respectively, from monocytes, endothelial HUVEC culture and monocytic THP cell culture by stimulation with lipopolysaccharides. Microparticles were counted by flow cytometry and titrated in microparticle-depleted normal plasma in the Thrombodynamics test. Monocyte microparticles induced the appearance of clotting centres through the TF pathway at concentrations approximately 100-fold lower than platelet and erythrocyte microparticles, which activated plasma by the contact pathway. For endothelial microparticles, both activation pathways were essential, and their activity was intermediate. Monocyte microparticles induced plasma clotting by the appearance of hundreds of clots with an extremely slow growth rate, while erythrocyte microparticles induced the appearance of a few clots with a growth rate similar to that from surface covered with high-density tissue factor. Patterns of clotting induced by platelet and endothelial microparticles were intermediate. Platelet, erythrocyte and endothelial microparticles impacts on the rate of clot growth from the surface with tissue factor did not differ significantly within the 0–200·103/ul range of microparticles concentrations. However, at concentrations greater than 500·103/ul, erythrocyte microparticles increased the stationary clot growth rate to significantly higher levels than do platelet microparticles or artificial phospholipid vesicles consisting of phosphatidylcholine and phosphatidylserine. Microparticles of different origins demonstrated qualitatively different characteristics related to coagulation activation and propagation.
- 29 May 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (5) , e0227932
Open AccessUse of Thrombodynamics for revealing the participation of platelet, erythrocyte, endothelial, and monocyte microparticles in coagulation activation and propagation
For many pathological states, microparticles are supposed to be one of the causes of hypercoagulation. Although there are some indirect data about microparticles participation in coagulation activation and propagation, the integral hemostasis test Thrombodynamics allows to measure micropaticles participation in these two coagulation phases directly. Demonstrates microparticles participation in coagulation activation by influence on the appearance of coagulation centres in the plasma volume and the rate of clot growth from the surface with immobilized tissue factor.Methods: Microparticles were obtained from platelets and erythrocytes by stimulation with thrombin receptor-activating peptide (SFLLRN) and calcium ionophore (A23187), respectively, from monocytes, endothelial HUVEC culture and monocytic THP cell culture by stimulation with lipopolysaccharides. Microparticles were counted by flow cytometry and titrated in microparticle-depleted normal plasma in the Thrombodynamics test. Monocyte microparticles induced the appearance of clotting centres through the TF pathway at concentrations approximately 100-fold lower than platelet and erythrocyte microparticles, which activated plasma by the contact pathway. For endothelial microparticles, both activation pathways were essential, and their activity was intermediate. Monocyte microparticles induced plasma clotting by the appearance of hundreds of clots with an extremely slow growth rate, while erythrocyte microparticles induced the appearance of a few clots with a growth rate similar to that from surface covered with high-density tissue factor. Patterns of clotting induced by platelet and endothelial microparticles were intermediate. Platelet, erythrocyte and endothelial microparticles impacts on the rate of clot growth from the surface with tissue factor did not differ significantly within the 0–200·103/ul range of microparticles concentrations. However, at concentrations greater than 500·103/ul, erythrocyte microparticles increased the stationary clot growth rate to significantly higher levels than do platelet microparticles or artificial phospholipid vesicles consisting of phosphatidylcholine and phosphatidylserine. Microparticles of different origins demonstrated qualitatively different characteristics related to coagulation activation and propagation.
- 28 November 2019
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 4(80),p. 21-29
Comparison of platelet aggregation parameters and expression of platelet granule markers
Введение. Активация тромбоцитов стимулирует их агрегацию и ассоциированный с секрецией экзоцитоз внутриклеточных гранул. Агрегацию чаще всего изучают турбидиметрическим методом, а экзоцитоз гранул методом проточной цитофлуориметрии, определяя экспрессию их маркеров на поверхности тромбоцитов. Цель исследования: сравнение чувствительности двух методов оценки активации тромбоцитов, исследования их агрегации и экспрессии маркеров внутриклеточных гранул. Материалы и методы. Тромбоциты здоровых доноров активировали АДФ и пептидом, активирующим рецептор тромбина (thrombin receptor activating peptide, TRAP). Агрегацию тромбоцитов изучали турбидиметрическим методом в обогащенной тромбоцитами плазме, регистрируя максимальный уровень светопропускания (Т макс). Экспрессию маркеров гранул изучали в цельной крови с помощью проточной цитофлуориметрии, регистрируя процент тромбоцитов, окрашенных антителами против маркеров альфагранул (CD62P) и плотных гранул (CD63). Результаты. У всех доноров 20 мкМ АДФ и 10 мкМ TRAP стимулировали мощную, необратимую агрегацию тромбоцитов (62,1 10,3 и 65,1 5,1 T макс, соответственно). Средние уровни агрегации были ниже при ее стимуляции 2,5 мкМ АДФ (30,9 23,2 T макс) и 1 мкМ TRAP (24,4 29,1 T макс). Экспрессия маркеров гранул была максимальной при активации тромбоцитов 10 мкМ TRAP (77,6 13,7 CD62P и 73,9 13,3 CD63), ниже при активации 1 мкМ TRAP (46,3 25,1 CD62P и 38,3 23,8 CD63), еще ниже при активации 20 мкМ АДФ (19,8 8,5 CD62P и 13,6 5,2 CD63) и минимальной при активации 2,5 мкМ АДФ (8,0 4,2 CD62P и 8,3 3,3 CD63). Адреналин (20 мкМ) не стимулировал экспрессию маркеров гранул, но при совместном добавлении с 20 мкМ АДФ повышал ее в 1,9 раза для обоих маркеров CD62P и CD63. Заключение. При активации тромбоцитов АДФ исследование агрегации является более чувствительным методом, чем определение экспрессии маркеров гранул. При активации тромбоцитов TRAP чувствительность обоих методов приблизительно одинакова. Экспрессия маркеров гранул увеличивается при совместном добавлении к тромбоцитам АДФ и адреналина, хотя адреналин сам по себе не стимулирует их экспрессию. Introduction. Platelet activation stimulates their aggregation and secretion associated exocytosis of intracellular granules. Aggregation is usually studied by turbidimetric method and granule exocytosis by detecting expression of their markers on platelet surface using flow cytofluorimetry. Aim: сomparison of the sensitivity of two methods for evaluation of platelet activation, studies of their aggregation and expression of intracellular granule markers. Materials and methods. Healthy donors platelets were activated by ADP and thrombin receptor activating peptide (TRAP). Platelet aggregation was investigated in platelet rich plasma by turbidimetric method, assessed by the maximal level of light transmission (T max). Expression of granule markers was detected in whole blood by fl ow cytofl uorimetry registering the percent of platelets stained with antibodies against the markers of alphagranules (CD62P) and dense granules (CD63). Results. In all donors 20 M ADP and 10 M TRAP stimulated strong irreversible platelet aggregation (62.1 10.3 and 65.1 5.1 T max). Mean aggregation levels were lower when it was stimulated by 2.5 M ADP (30.9 23.2 T max) and 1 M TRAP (24.4 29.1 T max). Expression of granule markers was maximal at platelet activation by 10 M TRAP (77.6 13.7 CD62P and 73.9 13.3 CD63), lower at activation by 1 M TRAP (46.3 25.1 CD62P and 38.3 23.8 CD63), more lower at activation by 20 M ADP (19.8 8.5 CD62P and 13.6 5.4 CD63), and minimal at activation by 2.5 M ADP (8.0 4.2 CD62P and 8.3 3.3 CD63). Epinephrine (20 M) did not stimulate expression of granule markers but at combined addition with 20 M ADP increased its level by 1.9 for both markers, CD62P and CD63. Conclusion. Platelet aggregation is more sensitive method than detection of expression of granule markers when platelets are activated by ADP. Both methods demonstrate about the same sensitivity when platelets are activated by TRAP. Expression of granule markers is increased at combined addition of ADP and epinephrine although epinephrine by itself fails to stimulate their expression.
- 28 November 2019
- Published by Cifra Ltd - Russian Agency for Digital Standardization (RADS) in Тромбоз, гемостаз и реология
- No. 4(80),p. 21-29
Comparison of platelet aggregation parameters and expression of platelet granule markers
Введение. Активация тромбоцитов стимулирует их агрегацию и ассоциированный с секрецией экзоцитоз внутриклеточных гранул. Агрегацию чаще всего изучают турбидиметрическим методом, а экзоцитоз гранул методом проточной цитофлуориметрии, определяя экспрессию их маркеров на поверхности тромбоцитов. Цель исследования: сравнение чувствительности двух методов оценки активации тромбоцитов, исследования их агрегации и экспрессии маркеров внутриклеточных гранул. Материалы и методы. Тромбоциты здоровых доноров активировали АДФ и пептидом, активирующим рецептор тромбина (thrombin receptor activating peptide, TRAP). Агрегацию тромбоцитов изучали турбидиметрическим методом в обогащенной тромбоцитами плазме, регистрируя максимальный уровень светопропускания (Т макс). Экспрессию маркеров гранул изучали в цельной крови с помощью проточной цитофлуориметрии, регистрируя процент тромбоцитов, окрашенных антителами против маркеров альфагранул (CD62P) и плотных гранул (CD63). Результаты. У всех доноров 20 мкМ АДФ и 10 мкМ TRAP стимулировали мощную, необратимую агрегацию тромбоцитов (62,1 10,3 и 65,1 5,1 T макс, соответственно). Средние уровни агрегации были ниже при ее стимуляции 2,5 мкМ АДФ (30,9 23,2 T макс) и 1 мкМ TRAP (24,4 29,1 T макс). Экспрессия маркеров гранул была максимальной при активации тромбоцитов 10 мкМ TRAP (77,6 13,7 CD62P и 73,9 13,3 CD63), ниже при активации 1 мкМ TRAP (46,3 25,1 CD62P и 38,3 23,8 CD63), еще ниже при активации 20 мкМ АДФ (19,8 8,5 CD62P и 13,6 5,2 CD63) и минимальной при активации 2,5 мкМ АДФ (8,0 4,2 CD62P и 8,3 3,3 CD63). Адреналин (20 мкМ) не стимулировал экспрессию маркеров гранул, но при совместном добавлении с 20 мкМ АДФ повышал ее в 1,9 раза для обоих маркеров CD62P и CD63. Заключение. При активации тромбоцитов АДФ исследование агрегации является более чувствительным методом, чем определение экспрессии маркеров гранул. При активации тромбоцитов TRAP чувствительность обоих методов приблизительно одинакова. Экспрессия маркеров гранул увеличивается при совместном добавлении к тромбоцитам АДФ и адреналина, хотя адреналин сам по себе не стимулирует их экспрессию. Introduction. Platelet activation stimulates their aggregation and secretion associated exocytosis of intracellular granules. Aggregation is usually studied by turbidimetric method and granule exocytosis by detecting expression of their markers on platelet surface using flow cytofluorimetry. Aim: сomparison of the sensitivity of two methods for evaluation of platelet activation, studies of their aggregation and expression of intracellular granule markers. Materials and methods. Healthy donors platelets were activated by ADP and thrombin receptor activating peptide (TRAP). Platelet aggregation was investigated in platelet rich plasma by turbidimetric method, assessed by the maximal level of light transmission (T max). Expression of granule markers was detected in whole blood by fl ow cytofl uorimetry registering the percent of platelets stained with antibodies against the markers of alphagranules (CD62P) and dense granules (CD63). Results. In all donors 20 M ADP and 10 M TRAP stimulated strong irreversible platelet aggregation (62.1 10.3 and 65.1 5.1 T max). Mean aggregation levels were lower when it was stimulated by 2.5 M ADP (30.9 23.2 T max) and 1 M TRAP (24.4 29.1 T max). Expression of granule markers was maximal at platelet activation by 10 M TRAP (77.6 13.7 CD62P and 73.9 13.3 CD63), lower at activation by 1 M TRAP (46.3 25.1 CD62P and 38.3 23.8 CD63), more lower at activation by 20 M ADP (19.8 8.5 CD62P and 13.6 5.4 CD63), and minimal at activation by 2.5 M ADP (8.0 4.2 CD62P and 8.3 3.3 CD63). Epinephrine (20 M) did not stimulate expression of granule markers but at combined addition with 20 M ADP increased its level by 1.9 for both markers, CD62P and CD63. Conclusion. Platelet aggregation is more sensitive method than detection of expression of granule markers when platelets are activated by ADP. Both methods demonstrate about the same sensitivity when platelets are activated by TRAP. Expression of granule markers is increased at combined addition of ADP and epinephrine although epinephrine by itself fails to stimulate their expression.
- Open Access
- 4 October 2019
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 64 (2) , 198-210-210
DIAGNOSTIC MARKERS AND PREDICTORS OF NEONATAL IMMUNE THROMBOCYTOPENIA
ДИАГНОСТИЧЕСКИЕ МАРКЕРЫ И ПРЕДИКТОРЫ НЕОНАТАЛЬНОЙ ИММУННОЙ ТРОМБОЦИТОПЕНИИ
- 4 October 2019
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 64 (2) , 198-210-210
Open AccessDIAGNOSTIC MARKERS AND PREDICTORS OF NEONATAL IMMUNE THROMBOCYTOPENIA
ДИАГНОСТИЧЕСКИЕ МАРКЕРЫ И ПРЕДИКТОРЫ НЕОНАТАЛЬНОЙ ИММУННОЙ ТРОМБОЦИТОПЕНИИ
- 30 September 2019
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- No. 3 part: 14,p. 35-37
Коагуляционные свойства мембранных микрочастиц тромбоцитов, эритроцитов, лейкоцитов и эндотелиальных клеток
Мембранные микрочастицы (МЧ) образуются при активации и/или повреждении клеток. Они обладают коагуляционной активностью (ускоряют свертывание крови), так как содержат на своей поверхности фосфатидилсерин субстрат для образования коагуляционных комплесов, а некоторые из них тканевой фактор (ТФ), главный инициатор коагуляционных реакций. Циркулирующие в кровотоке МЧ продуцируются клетками крови и эндотелиальными клетками сосудистой стенки, и их содержание может меняться при различных патологических состояниях. Сравнительные in vitro исследования показали, что наибольшей способностью ускорять свертывание плазмы крови обладают МЧ моноцитов и эндотелиальных клеток и более низкой МЧ тромбоцитов, эритроцитов и гранулоцитов (нейтрофиU лов). Эти различия обусловлены главным образом присутствием в МЧ моноцитов и эндотелиальных клеток активного ТФ и отсутствием его в МЧ тромбоцитов, эритроцитов и гранулоцитов. Вариации размера МЧ различного клеточного происхождения существенно не влияют на их коагуляционные свойства. Таким образом, на коагуляционный (протромботический) потенциал крови могут оказывать влияние в первую очередь МЧ, экспрессирующие ТФ, источником которых могут быть активированные и/или поврежденные моноциты и эндотелиальные клетки.Membrane microparticles (MPs) are formed upon cell activation and/or damage. They possess coagulation activity (accelerate blood clotting) since they contain on their surface posphatidylserine, substrate for assembling coagulation complexes, and some of them tissue factor (TF), major initiator of coagulation reactions. Circulating MPs are produced by blood cells and vessel wall endothelial cells and their amount could be changed in different pathological conditions. Comparative in vitro studies have shown that MPs derived from monocytes and endothelial cells have the highest and MPs derived from platelets, erythrocytes and granulocytes (neutrophils) much lower ability to accelerate blood plasma clotting. These differences are mainly determined by the presence of active TF in monocyte and endothelial MPs and its absence in platelet, erythrocyte and granulocyte MPs. Size variations of MPs of different cellular origin do not significantly affect their coagulation properties. Thus, coagulation (prothrombotic) blood potential could be influenced first of all by TF expressing MPs the source of which are activated and/or damaged monocytes and endothelial cells.
- 30 September 2019
- Published by Media Sphere Publishing Group in Russian Cardiology Bulletin
- No. 3 part: 14,p. 35-37
Коагуляционные свойства мембранных микрочастиц тромбоцитов, эритроцитов, лейкоцитов и эндотелиальных клеток
Мембранные микрочастицы (МЧ) образуются при активации и/или повреждении клеток. Они обладают коагуляционной активностью (ускоряют свертывание крови), так как содержат на своей поверхности фосфатидилсерин субстрат для образования коагуляционных комплесов, а некоторые из них тканевой фактор (ТФ), главный инициатор коагуляционных реакций. Циркулирующие в кровотоке МЧ продуцируются клетками крови и эндотелиальными клетками сосудистой стенки, и их содержание может меняться при различных патологических состояниях. Сравнительные in vitro исследования показали, что наибольшей способностью ускорять свертывание плазмы крови обладают МЧ моноцитов и эндотелиальных клеток и более низкой МЧ тромбоцитов, эритроцитов и гранулоцитов (нейтрофиU лов). Эти различия обусловлены главным образом присутствием в МЧ моноцитов и эндотелиальных клеток активного ТФ и отсутствием его в МЧ тромбоцитов, эритроцитов и гранулоцитов. Вариации размера МЧ различного клеточного происхождения существенно не влияют на их коагуляционные свойства. Таким образом, на коагуляционный (протромботический) потенциал крови могут оказывать влияние в первую очередь МЧ, экспрессирующие ТФ, источником которых могут быть активированные и/или поврежденные моноциты и эндотелиальные клетки.Membrane microparticles (MPs) are formed upon cell activation and/or damage. They possess coagulation activity (accelerate blood clotting) since they contain on their surface posphatidylserine, substrate for assembling coagulation complexes, and some of them tissue factor (TF), major initiator of coagulation reactions. Circulating MPs are produced by blood cells and vessel wall endothelial cells and their amount could be changed in different pathological conditions. Comparative in vitro studies have shown that MPs derived from monocytes and endothelial cells have the highest and MPs derived from platelets, erythrocytes and granulocytes (neutrophils) much lower ability to accelerate blood plasma clotting. These differences are mainly determined by the presence of active TF in monocyte and endothelial MPs and its absence in platelet, erythrocyte and granulocyte MPs. Size variations of MPs of different cellular origin do not significantly affect their coagulation properties. Thus, coagulation (prothrombotic) blood potential could be influenced first of all by TF expressing MPs the source of which are activated and/or damaged monocytes and endothelial cells.
- Open Access
- 1 January 2017
- Published by Remedium, Ltd. in Atherothrombosis
- No. 1,p. 134-144-144
APTAMERS ARE NEW PHARMACOLOGICAL SUBSTANCES FOR THE DEVELOPMENT OF ANTICOAGULANTS
Аптамеры представляют собой новый класс олигонуклеотидных соединений, способных специфически взаимодействовать с различными молекулярными мишенями и ингибировать их активность. Аптамеры получают путем отбора из библиотеки случайно синтезированных олигонуклеотидов (длина от 20 до 60 нуклеотидов) по их способности к связыванию с молекулой-мишенью. В дальнейшем такие первичные аптамеры могут быть химически модифицированы с целью оптимизации их структуры и повышения стабильности. Аптамеры принято считать химическими (олигонуклеотидными) аналогами моноклональных антител, т. к. они обладают близкими к антителам показателями специфичности и сродства (аффинности) по отношению к своим мишеням. Аптамеры активно используются для создания фармакологических препаратов. Как фармакологические субстанции они обладают рядом преимуществ перед антителами и другими белковыми молекулами. Аптамеры практически неиммуногенны, они синтезируются химическим путем без использования биологических продуцентов, и для них могут быть легко созданы антидоты на основе комплементарных последовательностей. В обзоре рассматриваются работы, направленные на создание новых антикоагулянтных препаратов аптамерной природы. Наиболее подробные исследования, как доклинические, так и клинические (в рамках различных фаз клинических испытаний), были выполнены при изучении аптамеров против фактора Виллебранда, фактора IX и тромбина.
- 1 January 2017
- Published by Remedium, Ltd. in Atherothrombosis
- No. 1,p. 134-144-144
Open AccessAPTAMERS ARE NEW PHARMACOLOGICAL SUBSTANCES FOR THE DEVELOPMENT OF ANTICOAGULANTS
Аптамеры представляют собой новый класс олигонуклеотидных соединений, способных специфически взаимодействовать с различными молекулярными мишенями и ингибировать их активность. Аптамеры получают путем отбора из библиотеки случайно синтезированных олигонуклеотидов (длина от 20 до 60 нуклеотидов) по их способности к связыванию с молекулой-мишенью. В дальнейшем такие первичные аптамеры могут быть химически модифицированы с целью оптимизации их структуры и повышения стабильности. Аптамеры принято считать химическими (олигонуклеотидными) аналогами моноклональных антител, т. к. они обладают близкими к антителам показателями специфичности и сродства (аффинности) по отношению к своим мишеням. Аптамеры активно используются для создания фармакологических препаратов. Как фармакологические субстанции они обладают рядом преимуществ перед антителами и другими белковыми молекулами. Аптамеры практически неиммуногенны, они синтезируются химическим путем без использования биологических продуцентов, и для них могут быть легко созданы антидоты на основе комплементарных последовательностей. В обзоре рассматриваются работы, направленные на создание новых антикоагулянтных препаратов аптамерной природы. Наиболее подробные исследования, как доклинические, так и клинические (в рамках различных фаз клинических испытаний), были выполнены при изучении аптамеров против фактора Виллебранда, фактора IX и тромбина.
- 5 August 1996
- Published by Wiley in FEBS Letters
- Vol. 391 (1-2) , 84-88
Stimulation of platelet glycoprotein IIb-IIIa (αIIbβ3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa
Platelet glycoprotein (GP) IIb-IIIa complex (αIIbβ3-integrin) changes its conformation upon platelet activation that results in binding of RGD-containing ligands and expression of ligand-induced binding site (LIBS) neoepitopes. Anti-GIIb-IIIa monoclonal antibody (monAB) CRC54 bound to ≤10% of GPIIb-IIIa on resting platelets but binding was enhanced by the occupation of GPIIb-IIIa with RGDS peptide and by platelet activation indicating that CRC54 is directed against LIBS epitope. The epitope was located within the first 100 N-terminal residues of GPIIIa and differed from other LIBS epitopes. CRC54 as well as its Fab fragments were able to induce platelet aggregation. CRC54 also stimulated interaction of GPIIb-IIIa with its ligands (fibrinogen and fibronectin) and conformation-dependent antibodies. The results indicated that changes of GPIIb-IIIa conformation, binding of ligands and platelet aggregation could be stimulated via interaction of anti-LIBS antibody with the N-terminal part of GPIIIa.
- 5 August 1996
- Published by Wiley in FEBS Letters
- Vol. 391 (1-2) , 84-88
Stimulation of platelet glycoprotein IIb-IIIa (αIIbβ3-integrin) functional activity by a monoclonal antibody to the N-terminal region of glycoprotein IIIa
Platelet glycoprotein (GP) IIb-IIIa complex (αIIbβ3-integrin) changes its conformation upon platelet activation that results in binding of RGD-containing ligands and expression of ligand-induced binding site (LIBS) neoepitopes. Anti-GIIb-IIIa monoclonal antibody (monAB) CRC54 bound to ≤10% of GPIIb-IIIa on resting platelets but binding was enhanced by the occupation of GPIIb-IIIa with RGDS peptide and by platelet activation indicating that CRC54 is directed against LIBS epitope. The epitope was located within the first 100 N-terminal residues of GPIIIa and differed from other LIBS epitopes. CRC54 as well as its Fab fragments were able to induce platelet aggregation. CRC54 also stimulated interaction of GPIIb-IIIa with its ligands (fibrinogen and fibronectin) and conformation-dependent antibodies. The results indicated that changes of GPIIb-IIIa conformation, binding of ligands and platelet aggregation could be stimulated via interaction of anti-LIBS antibody with the N-terminal part of GPIIIa.